A new clinical study has shown that the body can now manage sickle cell anemia on its own, potentially eliminating the need for future external interventions. This therapy significantly improves blood circulation in the brain, thereby reducing the risk of stroke and cognitive impairments. This is no longer just temporary symptom management; it’s a targeted and in-depth treatment.
Sickle cell anemia is a genetic disorder where red blood cells take on an abnormal, sickle (acute-angled) shape. These cells easily break apart, have difficulty moving through blood vessels, and cannot deliver oxygen to tissues effectively. Managing the disease becomes simpler with gene engineering as the problem is addressed at its root. This therapy is not only effective but also leads to fewer complications, such as infections, which are common issues with blood transfusions and bone marrow transplants.
The study included three patients with severe sickle cell anemia. Their stem cells were modified using gene engineering with CRISPR-Cas9 technology to increase the level of fetal hemoglobin (HbF). Fetal hemoglobin differs from adult hemoglobin and does not cause red blood cell deformation. Therefore, when HbF levels increase in the blood, it helps red blood cells function normally and reduces the severity of the disease. Twelve and 24 months after the therapy, blood flow in the patients’ brains improved and reached normal levels. No new stroke cases were reported, and hemoglobin levels increased significantly.
These results indicate that gene therapy may help patients with sickle cell anemia prevent stroke and cognitive decline, offering them a new treatment possibility.
Although the study was not large-scale, it clearly demonstrated that gene therapy not only alleviates symptoms but also reduces the risk of disease complications, providing hope for individuals battling this severe condition.
Reference
Sharma, A., Hankins, J. S., Boelens, J.-J., Cancio, M., Peddinti, R., Rispoli, L., Sloan, S., DiDominick Costa, S., Peled, S., Wiethoff, A., Sitaram, R., & LaBelle, J. L. (2025). Normalization of cerebral hemodynamics after gene therapy in adults with sickle cell disease. American Journal of Hematology. Advance online publication.
